Nuvation Bio (NUVB) Competitors

Nuvation Bio (NYSE:NUVB) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Do insiders and institutionals hold more shares of NUVB or IMVT?

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 5.1% of Nuvation Bio shares are held by company insiders. Comparatively, 5.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media prefer NUVB or IMVT?

In the previous week, Immunovant had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 13 mentions for Immunovant and 11 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 1.22 beat Immunovant's score of 1.16 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in NUVB or IMVT?

Immunovant received 78 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 81.82% of users gave Nuvation Bio an outperform vote while only 78.11% of users gave Immunovant an outperform vote.

Company	Underperform	Outperform
Nuvation Bio	Outperform Votes 54 81.82%	Underperform Votes 12 18.18%
Immunovant	Outperform Votes 132 78.11%	Underperform Votes 37 21.89%

Is NUVB or IMVT more profitable?

Nuvation Bio's return on equity of -21.89% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	N/A	-21.89%	-17.86%
Immunovant	N/A	-77.94%	-69.82%

Which has higher earnings and valuation, NUVB or IMVT?

Nuvation Bio has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$7.87M	87.11	-$75.80M	-$2.26	-0.90
Immunovant	N/A	N/A	-$259.34M	-$2.62	-5.90

Do analysts rate NUVB or IMVT?

Nuvation Bio currently has a consensus price target of $8.75, suggesting a potential upside of 332.10%. Immunovant has a consensus price target of $41.00, suggesting a potential upside of 165.03%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Immunovant	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more volatility & risk, NUVB or IMVT?

Nuvation Bio has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Summary

Nuvation Bio beats Immunovant on 12 of the 16 factors compared between the two stocks.